Loading...
New

Cystic Fibrosis (CF) Therapeutics Market by Drug Class (Pancreatic Enzyme Supplements, Mucolytic, Bronchodilators, and CFTR Modulators) and Route of Administration (Oral and Inhaled): Global Opportunity Analysis and Industry Forecast, 2019-2026

A05134
Pages: 187
Nov 2019 | 1332 Views
 
Author(s) : Kavita Joshi , Onkar Sumant
Tables: 143
Charts: 37
 

Cystic Fibrosis Therapeutics Market Outlook - 2026

The global cystic fibrosis therapeutics market size was valued at $4,615.4 million in 2018 and is expected to reach $9,277.3 million by 2026, registering a CAGR of 9.2% from 2019 to 2026. 

Cystic fibrosis is a hereditary disorder, which majorly affects lungs and other body parts such as pancreas, liver, and kidney. It is caused by the mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. This gene is located in chromosome number 7, and is responsible for the regulation of sweat, mucus, and body secretions. However, mutation of this gene leads to absence of CFTR activity, which in turn results in loss of chloride and alters the protein structure. Patients experience difficulty in breathing, mucus formation, fatty stool, and difficulty in the passageway of the pancreas, bile duct, intestine, & salivary gland. Cystic fibrosis is diagnosed by the use of sweat test and genetic testing. Physical therapy is used for the treatment of cystic fibrosis that helps in the reduction of mucus formation and fights against infections of an organ. In addition, treatment of cystic fibrosis includes the use of drugs such as Pulmozyme, Kalydeco, and others. These drugs can be administered to the patient by different routes such as oral and by inhalation. 

Cystic Fibrosis Therapeutics Market

Get more information on this report : Request Sample Pages

The global cystic fibrosis therapeutics market is expected to witness significant growth during the forecast period majorly due to availability of personalized drug therapy & molecular prosthetics for the treatment of cystic fibrosis. Furthermore, rise in prevalence of cystic fibrosis and surge in awareness about cystic fibrosis across the globe boost the cystic fibrosis market trend. For instance, according to the Cystic Fibrosis Foundation Patient Registry, in the U.S. more than 30,000 people are living with cystic fibrosis and more than 70,000 worldwide. In addition, approximately 1,000 new cases of CF are diagnosed each year and more than 75 % of people with CF are diagnosed by age 2. Moreover, increase in R&D investments made by government in the healthcare sector drives the cystic fibrosis therapeutics market growth. However, high cost of the cystic fibrosis treatment and introduction of generic drugs hinder the growth of the market. Developing nations such as countries of Asia-Pacific region are not so aware reading the cystic fibrosis diagnosis of the newborns. Further, in various countries, new born are not tested for CF during birth and national registries are lacking in data, thereby hampering the cystic fibrosis market growth. On the contrary, the introduction of various new drugs with better productivity and development of the healthcare R&D facilities are expected to create lucrative opportunities in the cystic fibrosis therapeutics market. Moreover, development of the healthcare industry and increase in R&D activities undertaken by key players are expected to boost the market growth during the forecast period. Furthermore, rise in prevalence of cystic fibrosis has generated need for newer and advanced therapeutics for its treatment. Hence, this has led to increase in number of pipeline drugs in the market, which is expected to provide remunerative opportunities for market expansion during the forecast period.

Global Cystic Fibrosis Therapeutics Market Segmentation

The global cystic fibrosis therapeutic market is segmented on the basis of drug class, route of administration, top selling drug, and region. On the basis of drug class, the market is divided into pancreatic enzyme supplements, mucolytic, bronchodilators, and CFTR modulators. Depending on route of administration, it is classified into oral and inhaled. By top selling drug, the market is segregated into pulmozyme, Creon, kalydeco, cayston, azithromycin, tobramycin and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Drug Class segment review

Based on cystic fibrosis therapeutics market analysis, the CFTR modulators segment dominated the market in 2018 and is anticipated to continue its dominance during the forecast period. This is attributed to increased usage of these drugs for the treatment of cystic fibrosis. This segment is also estimated to grow at the fastest rate during the forecast period. Further, the introduction of CFTR drugs, Kalydeco, Orkambi and Symdeko is one such innovation. These drugs are now widely being used for the treatment of cystic fibrosis and many other CFTR drugs are under clinical trials. The main target of these drugs is to increase the life expectancy of the patients. Moreover, advances in the diagnosis and therapeutics has significantly increased the survival of patients.

Cystic Fibrosis (CF) Therapeutics Market
By Drug Class

Your browser does not support the canvas element.

CFTR modulators segment is projected as one of the most lucrative segments.

Get more information on this report : Request Sample Pages

Route of Administration segment review

By route of administration, the oral segment accounted for the majority of the cystic fibrosis therapeutics market share in 2018, owing to the increased formulation of drugs in oral form; for example, development of CFTR drugs. Further, there are currently three CFTR modulator drugs approved by the U.S. FDA, all of which are oral tablets. These include ivacaftor (kalydeco), orkambi, and symdeko. The market for these oral drugs is anticipated to grow at a fast pace owing to ongoing clinical trials and research & development toward the development of oral CFTR drugs.

Cystic Fibrosis (CF) Therapeutics Market
By Route of Administration

Your browser does not support the canvas element.

Oral route of administration is projected as one of the most lucrative segments.

Get more information on this report : Request Sample Pages

Europe constitutes the highest market share in the global cystic fibrosis therapeutics market in 2018, followed by North America owing to the increase in incidence of cystic fibrosis. Moreover, increase in governmental support for innovation and rise in funding of projects for R&D of various cystic fibrosis drugs further fuel the market growth in this region. UK is the highest revenue contributor due to increase in prevalence of cystic fibrosis in this region. Moreover, surge in national newborn screening program in the UK propels the market growth. In addition, many companies are involved in developing drugs for individuals who do not get benefitted with CFTR drugs. However, North America is projected to grow at the highest CAGR during the forecast period.

Key players operating in cystic fibrosis therapeutic markets are Genentech, Inc., Novartis AG, Gilead Sciences, Inc., Vertex Pharmaceuticals Incorporated, AbbVie Inc., GlaxoSmithKline Plc., Johnson & Johnson, Allergan plc, Pharmaxis Ltd., and Mylan N.V.

Cystic Fibrosis (CF) Therapeutics Market
By Region

2026
Europe 
North America
Asia-pacific
Lamea

North America region would exhibit the highest CAGR of 9.9% during 2019-2026.

Get more information on this report : Request Sample Pages

Key Benefits for Cystic Fibrosis Therapeutics Market :

  • The cystic fibrosis therapeutics market share is based on a comprehensive analysis of key developments in the cystic fibrosis industry.
  • The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the global cystic fibrosis therapeutics market.
  • The cystic fibrosis therapeutics market trends are studied from 2018 to 2026.
  • Information about key drivers, restrains, and opportunities and their impact analysis on the cystic fibrosis therapeutics market size is provided.
  • Porter’s five forces analysis illustrates the potency of buyers and suppliers operating in the industry.
  • The quantitative analysis of the global cystic fibrosis therapeutics market forecast from 2019 to 2026 is provided to determine the market potential.

Cystic Fibrosis Therapeutics Market Segments:

By Drug Class

  • Pancreatic Enzyme Supplements
  • Mucolytic
  • Bronchodilators
  • CFTR modulators

By Route of Administration 

  • Oral 
  • Inhaled

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
 

CHAPTER 1:    INTRODUCTION

1.1.    Report description
1.2.    Key benefits for stakeholders
1.3.    Key market segments
1.4.    Research methodology

1.4.1.    Secondary research
1.4.2.    Primary research
1.4.3.    Analyst tools & models

CHAPTER 2:    EXECUTIVE SUMMARY

2.1.    CXO perspective

CHAPTER 3:    MARKET OVERVIEW

3.1.    Market definition and scope
3.2.    Porter’s five forces analysis
3.3.    Top Player Positioning
3.4.    Market dynamics

3.4.1.    Drivers

3.4.1.1.    Rise in incidence of cystic fibrosis (CF)
3.4.1.2.    Advancements in therapeutics for treatment of cystic fibrosis

3.4.2.    Restraints

3.4.2.1.    Low awareness in developing nations

3.4.3.    Opportunity

3.4.3.1.    Surge in R&D towards the development of novel therapeutics

CHAPTER 4:    CYSTIC FIBROSIS THERAPEUTICS MARKET, BY DRUG CLASS

4.1.    Overview

4.1.1.    Market size and forecast

4.2.    Pancreatic Enzyme Supplements

4.2.1.    Key market trends and opportunities
4.2.2.    Market size and forecast
4.2.3.    Market analysis, by country

4.3.    Mucolytics

4.3.1.    Key trends and opportunities
4.3.2.    Market size and forecast
4.3.3.    Market analysis, by country

4.4.    Bronchodilators

4.4.1.    Key market trends and opportunities
4.4.2.    Market size and forecast
4.4.3.    Market analysis, by country

4.5.    CFTR modulators

4.5.1.    Key trends and opportunities
4.5.2.    Market size and forecast
4.5.3.    Market analysis, by country

CHAPTER 5:    CYSTIC FIBROSIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION

5.1.    Overview

5.1.1.    Market size and forecast

5.2.    Oral

5.2.1.    Market size and forecast
5.2.2.    Market analysis, by country

5.3.    Inhale

5.3.1.    Market size and forecast
5.3.2.    Market analysis, by country

CHAPTER 6:    CYSTIC FIBROSIS THERAPEUTICS MARKET, BY REGION

6.1.    Overview

6.1.1.    Market size and forecast

6.2.    North America

6.2.1.    Key trends and opportunities
6.2.2.    North America market size and forecast, by country

6.2.2.1.    U.S. market size and forecast, by drug class
6.2.2.2.    U.S. market size and forecast, by route of administration
6.2.2.3.    Canada market size and forecast, by drug class
6.2.2.4.    Canada market size and forecast, by route of administration
6.2.2.5.    Mexico market size and forecast, by drug class
6.2.2.6.    Mexico market size and forecast, by route of administration

6.2.3.    North America market size and forecast, by drug class
6.2.4.    North America market size and forecast, by route of administration

6.3.    Europe

6.3.1.    Key trends and opportunities
6.3.2.    Europe market size and forecast, by country

6.3.2.1.    Germany market size and forecast, by drug class
6.3.2.2.    Germany market size and forecast, by route of administration
6.3.2.3.    UK market size and forecast, by drug class
6.3.2.4.    UK market size and forecast, by route of administration
6.3.2.5.    France market size and forecast, by drug class
6.3.2.6.    France market size and forecast, by route of administration
6.3.2.7.    Rest of Europe market size and forecast, by drug class
6.3.2.8.    Rest of Europe market size and forecast, by route of administration

6.3.3.    Europe market size and forecast, by drug class

6.4.    Asia-Pacific

6.4.1.    Key trends and opportunities
6.4.2.    Asia-Pacific market size and forecast, by country

6.4.2.1.    Japan market size and forecast, by drug class
6.4.2.2.    Japan market size and forecast, by route of administration
6.4.2.3.    China market size and forecast, by drug class
6.4.2.4.    China market size and forecast, by route of administration
6.4.2.5.    India market size and forecast, by drug class
6.4.2.6.    India market size and forecast, by route of administration
6.4.2.7.    Australia market size and forecast, by drug class
6.4.2.8.    Australia market size and forecast, by route of administration
6.4.2.9.    Rest of Asia-Pacific market size and forecast, by drug class
6.4.2.10.    Rest of Asia-Pacific market size and forecast, by route of administration

6.4.3.    Asia-Pacific market size and forecast, by drug class
6.4.4.    Asia-Pacific market size and forecast, by route of administration

6.5.    LAMEA

6.5.1.    Key market trends and opportunities
6.5.2.    LAMEA market size and forecast, by country

6.5.2.1.    Brazil market size and forecast, by drug class
6.5.2.2.    Brazil market size and forecast, by route of administration
6.5.2.3.    South Africa market size and forecast, by drug class
6.5.2.4.    South Africa market size and forecast, by route of administration
6.5.2.5.    Saudi Arabia market size and forecast, by drug class
6.5.2.6.    Saudi Arabia market size and forecast, by route of administration
6.5.2.7.    Rest of LAMEA market size and forecast, by drug class
6.5.2.8.    Rest of LAMEA market size and forecast, by route of administration

6.5.3.    LAMEA market size and forecast, by drug class
6.5.4.    LAMEA market size and forecast, by route of administration

CHAPTER 7:    COMPANY PROFILES

7.1.    F. Hoffmann-La Roche AG

7.1.1.    Company overview
7.1.2.    Company snapshot
7.1.3.    Operating business segments
7.1.4.    Product portfolio
7.1.5.    Business performance

7.2.    Novartis AG

7.2.1.    Company overview
7.2.2.    Company snapshot
7.2.3.    Operating business segments
7.2.4.    Product portfolio
7.2.5.    Business performance

7.3.    Gilead Sciences, Inc.

7.3.1.    Company overview
7.3.2.    Company snapshot
7.3.3.    Operating business segments
7.3.4.    Product portfolio
7.3.5.    Business performance

7.4.    Vertex Pharmaceuticals Incorporated

7.4.1.    Company overview
7.4.2.    Company snapshot
7.4.3.    Operating business segments
7.4.4.    Product portfolio
7.4.5.    Business performance
7.4.6.    Key strategic moves and developments

7.5.    AbbVie Inc.

7.5.1.    Company overview
7.5.2.    Company snapshot
7.5.3.    Operating business segments
7.5.4.    Product portfolio
7.5.5.    Business performance
7.5.6.    Key strategic moves and developments

7.6.    GlaxoSmithKline Plc.

7.6.1.    Company overview
7.6.2.    Company snapshot
7.6.3.    Operating business segments
7.6.4.    Product portfolio
7.6.5.    Business performance

7.7.    Teva Pharmaceutical  Industries Ltd.

7.7.1.    Company overview
7.7.2.    Company snapshot
7.7.3.    Operating business segments
7.7.4.    Product portfolio
7.7.5.    Business performance

7.8.    Allergan plc

7.8.1.    Company overview
7.8.2.    Company snapshot
7.8.3.    Operating business segments
7.8.4.    Product portfolio
7.8.5.    Business performance

7.9.    Pharmaxis Ltd

7.9.1.    Company overview
7.9.2.    Company snapshot
7.9.3.    Operating business segments
7.9.4.    Product portfolio

7.10.    Mylan N.V

7.10.1.    Company overview
7.10.2.    Company snapshot
7.10.3.    Operating business segments
7.10.4.    Product portfolio
7.10.5.    Business performance

LIST OF TABLES

TABLE 01.    GLOBAL CYSTIC FIBROSIS THERAPEUTICS MARKET, BY DRUG CLASS, 2018–2026 ($MILLION)
TABLE 02.    GLOBAL PANCREATIC ENZYME SUPPLEMENTS, BY REGION, 2018–2026 ($MILLION)
TABLE 03.    LIST OF MUCOLYTICS USED TO TREAT CYSTIC FIBROSIS
TABLE 04.    GLOBAL MUCOLYTICS CYSTIC FIBROSIS THERAPEUTICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 05.    LIST OF BRONCHODILATORS USED TO TREAT CYSTIC FIBROSIS
TABLE 06.    GLOBAL BRONCHODILATORS CYSTIC FIBROSIS THERAPEUTICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 07.    LIST OF CFTRS USED TO TREAT CYSTIC FIBROSIS
TABLE 08.    GLOBAL CFTR MODULATOR MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 09.    GLOBAL CYSTIC FIBROSIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 10.    GLOBAL CYSTIC FIBROSIS THERAPEUTICS MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY REGION, 2018–2026 ($MILLION)
TABLE 11.    GLOBAL CYSTIC FIBROSIS THERAPEUTICS MARKET FOR INHALE ROUTE OF ADMINISTRATION, BY REGION, 2018–2026 ($MILLION)
TABLE 12.    GLOBAL CYSTIC FIBROSIS THERAPEUTICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 13.    NORTH AMERICA CYSTIC FIBROSIS THERAPEUTICS MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 14.    U.S. CYSTIC FIBROSIS THERAPEUTICS MARKET, BY DRUG CLASS, 2018–2026 ($MILLION)
TABLE 15.    U.S. CYSTIC FIBROSIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 16.    CANADA CYSTIC FIBROSIS THERAPEUTICS MARKET, BY DRUG CLASS, 2018–2026 ($MILLION)
TABLE 17.    CANADA CYSTIC FIBROSIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 18.    MEXICO CYSTIC FIBROSIS THERAPEUTICS MARKET, BY DRUG CLASS, 2018–2026 ($MILLION)
TABLE 19.    MEXICO CYSTIC FIBROSIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 20.    NORTH AMERICA CYSTIC FIBROSIS THERAPEUTICS MARKET, BY DRUG CLASS, 2018–2026 ($MILLION)
TABLE 21.    NORTH AMERICA CYSTIC FIBROSIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 22.    EUROPE CYSTIC FIBROSIS THERAPEUTICS MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 23.    GERMANY CYSTIC FIBROSIS THERAPEUTICS MARKET, BY DRUG CLASS, 2018–2026 ($MILLION)
TABLE 24.    GERMANY CYSTIC FIBROSIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 25.    UK CYSTIC FIBROSIS THERAPEUTICS MARKET, BY DRUG CLASS, 2018–2026 ($MILLION)
TABLE 26.    UK CYSTIC FIBROSIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 27.    FRANCE CYSTIC FIBROSIS THERAPEUTICS MARKET, BY DRUG CLASS, 2018–2026 ($MILLION)
TABLE 28.    FRANCE CYSTIC FIBROSIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 29.    REST OF EUROPE CYSTIC FIBROSIS THERAPEUTICS MARKET, BY DRUG CLASS, 2018–2026 ($MILLION)
TABLE 30.    REST OF EUROPE CYSTIC FIBROSIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 31.    EUROPE CYSTIC FIBROSIS THERAPEUTICS MARKET, BY DRUG CLASS, 2018–2026 ($MILLION)
TABLE 32.    ASIA-PACIFIC CYSTIC FIBROSIS THERAPEUTICS MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 33.    JAPAN CYSTIC FIBROSIS THERAPEUTICS MARKET, BY DRUG CLASS, 2018–2026 ($MILLION)
TABLE 34.    JAPAN CYSTIC FIBROSIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 35.    CHINA CYSTIC FIBROSIS THERAPEUTICS MARKET, BY DRUG CLASS, 2018–2026 ($MILLION)
TABLE 36.    CHINA CYSTIC FIBROSIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 37.    INDIA CYSTIC FIBROSIS THERAPEUTICS MARKET, BY DRUG CLASS, 2018–2026 ($MILLION)
TABLE 38.    INDIA CYSTIC FIBROSIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 39.    AUSTRALIA CYSTIC FIBROSIS THERAPEUTICS MARKET, BY DRUG CLASS, 2018–2026 ($MILLION)
TABLE 40.    AUSTRALIA CYSTIC FIBROSIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 41.    REST OF ASIA-PACIFIC CYSTIC FIBROSIS THERAPEUTICS MARKET, BY DRUG CLASS, 2018–2026 ($MILLION)
TABLE 42.    REST OF ASIA-PACIFIC CYSTIC FIBROSIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 43.    ASIA-PACIFIC CYSTIC FIBROSIS THERAPEUTICS MARKET, BY DRUG CLASS, 2018–2026 ($MILLION)
TABLE 44.    ASIA-PACIFIC CYSTIC FIBROSIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 45.    LAMEA CYSTIC FIBROSIS THERAPEUTICS MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 46.    BRAZIL CYSTIC FIBROSIS THERAPEUTICS MARKET, BY DRUG CLASS, 2018–2026 ($MILLION)
TABLE 47.    BRAZIL CYSTIC FIBROSIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 48.    SOUTH AFRICA CYSTIC FIBROSIS THERAPEUTICS MARKET, BY DRUG CLASS, 2018–2026 ($MILLION)
TABLE 49.    SOUTH AFRICA CYSTIC FIBROSIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 50.    SAUDI ARABIA CYSTIC FIBROSIS THERAPEUTICS MARKET, BY DRUG CLASS, 2018–2026 ($MILLION)
TABLE 51.    SAUDI ARABIA CYSTIC FIBROSIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 52.    REST OF LAMEA CYSTIC FIBROSIS THERAPEUTICS MARKET, BY DRUG CLASS, 2018–2026 ($MILLION)
TABLE 53.    REST OF LAMEA CYSTIC FIBROSIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 54.    LAMEA CYSTIC FIBROSIS THERAPEUTICS MARKET, BY DRUG CLASS, 2018–2026 ($MILLION)
TABLE 55.    LAMEA CYSTIC FIBROSIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 56.    ROCHE: COMPANY SNAPSHOT
TABLE 57.    ROCHE: OPERATING SEGMENTS
TABLE 58.    ROCHE PLC: PRODUCT PORTFOLIO
TABLE 59.    NOVARTIS AG INC.: COMPANY SNAPSHOT
TABLE 60.    NOVARTIS AG INC.: OPERATING SEGMENTS
TABLE 61.    NOVARTIS AG INC.: PRODUCT PORTFOLIO
TABLE 62.    GILEAD SCIENCES, INC.: COMPANY SNAPSHOT
TABLE 63.    GILEAD SCIENCES, INC.: OPERATING SEGMENTS
TABLE 64.    GILEAD SCIENCES, INC.: PRODUCT PORTFOLIO:
TABLE 65.    VERTEX PHARMACEUTICALS INCORPORATED: COMPANY SNAPSHOT
TABLE 66.    VERTEX PHARMACEUTICALS INCORPORATED: OPERATING SEGMENTS
TABLE 67.    VERTEX PHARMACEUTICALS INCORPORATED: PRODUCT PORTFOLIO
TABLE 68.    ABBVIE INC.: COMPANY SNAPSHOT
TABLE 69.    ABBVIE INC.: OPERATING SEGMENTS
TABLE 70.    ABBVIE INC.: PRODUCT PORTFOLIO
TABLE 71.    GLAXOSMITHKLINE PLC.: COMPANY SNAPSHOT
TABLE 72.    GLAXOSMITHKLINE PLC.: OPERATING SEGMENTS
TABLE 73.    GLAXOSMITHKLINE PLC.: PRODUCT PORTFOLIO
TABLE 74.    TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
TABLE 75.    TEVA PHARMACEUTICAL INDUSTRIES PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS
TABLE 76.    TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
TABLE 77.    ALLERGAN PLC: COMPANY SNAPSHOT
TABLE 78.    ALLERGAN PLC: OPERATING SEGMENTS
TABLE 79.    ALLERGAN PLC: PRODUCT PORTFOLIO
TABLE 80.    PHARMAXIS LTD: COMPANY SNAPSHOT
TABLE 81.    PHARMAXIS LTD: PRODUCT SEGMENTS
TABLE 82.    PHARMAXIS LTD: PRODUCT PORTFOLIO
TABLE 83.    MYLAN N.V.: COMPANY SNAPSHOT
TABLE 84.    MYLAN N.V.: OPERATING SEGMENTS
TABLE 85.    MYLAN N.V: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01.    CYSTIC FIBROSIS THERAPEUTICS MARKET SEGMENTATION
FIGURE 02.    LOW BARGAINING POWER OF SUPPLIERS
FIGURE 03.    HIGH BARGAINING POWER OF BUYERS
FIGURE 04.    HIGH THREAT OF SUBSTITUTION
FIGURE 05.    HIGH THREAT OF NEW ENTRANTS
FIGURE 06.    HIGH COMPETITIVE RIVALRY
FIGURE 07.    TOP PLAYER POSITIONING
FIGURE 08.    GLOBAL CYSTIC FIBROSIS THERAPEUTICS MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES
FIGURE 09.    COMPARATIVE SHARE ANALYSIS OF PANCREATIC ENZYME SUPPLEMENTS MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 10.    COMPARATIVE SHARE ANALYSIS OF MUCOLYTICS CYSTIC FIBROSIS THERAPEUTICS MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 11.    COMPARATIVE SHARE ANALYSIS OF BRONCHODILATORS CYSTIC FIBROSIS THERAPEUTICS MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 12.    COMPARATIVE SHARE ANALYSIS OF CFTR MODULATOR MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 13.    COMPARATIVE SHARE ANALYSIS OF CYSTIC FIBROSIS THERAPEUTICS MARKET FOR ORAL ROUTE OF ADMINISTRATION BY COUNTRY, 2018 & 2026 (%)
FIGURE 14.    COMPARATIVE SHARE ANALYSIS OF CYSTIC FIBROSIS THERAPEUTICS MARKET FOR INHALE ROUTE OF ADMINISTRATION BY COUNTRY, 2018 & 2026 (%)
FIGURE 15.    ROCHE: REVENUE SHARE BY GEOGRAPHY, 2018 (%)
FIGURE 16.    ROCHE: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 17.    ROCHE: REVENUE SHARE BY GEOGRAPHY, 2018 (%)
FIGURE 18.    NOVARTIS AG INC: NET SALES, 2016–2018 ($MILLION)
FIGURE 19.    NOVARTIS AG INC: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 20.    NOVARTIS AG INC..: REVENUE SHARE BY REGION, 2018(%)
FIGURE 21.    GILEAD SCIENCES INC.: NET SALES, 2016–2018 ($MILLION)
FIGURE 22.    GILEAD SCIENCES INC..: REVENUE SHARE BY REGION, 2018(%)
FIGURE 23.    GILEAD SCIENCES INC.: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 24.    VERTEX PHARMACEUTICAL INC..: NET SALES, 2016–2018 ($MILLION)
FIGURE 25.    VERTEX PHARMACEUTICAL INC.: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 26.    ABBVIE INC..: NET SALES, 2016–2018 ($MILLION)
FIGURE 27.    ABBVIE INC..: REVENUE SHARE BY REGIONS, 2018 (%)
FIGURE 28.    ABBVIE INC..: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 29.    GLAXOSMITHKLINE PLC.: NET SALES, 2016–2018 ($MILLION)
FIGURE 30.    GLAXOSMITHKLINE PLC.: REVENUE SHARE BY REGION, 2018(%)
FIGURE 31.    GLAXOSMITHKLINE PLC.: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 32.    TEVA PHARMACEUTICAL INDUSTRIES: NET SALES, 2016–2018 ($MILLION)
FIGURE 33.    TEVA PHARMACEUTICAL INDUSTRIES: REVENUE SHARE BY SEGMENTS 2018 ($MILLION)
FIGURE 34.    ALLERGAN PLC: NET SALES, 2016–2018 ($MILLION)
FIGURE 35.    ALLERGAN PLC: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 36.    MYLAN N.V.: NET SALES, 2016–2018 ($MILLION)
FIGURE 37.    MYLAN N.V.: REVENUE SHARE BY REGION, 2018(%)

 
 

According to CXOs, cystic fibrosis is a genetic disease that primarily affects the lungs and digestive system, but it can result in lethal disorders such as liver disease and diabetes. Symptoms of cystic fibrosis includes salty-tasting skin, persistent coughing, frequent lung infections including pneumonia or bronchitis, wheezing or shortness of breath, poor growth or weight gain in spite of a good appetite, frequent greasy, bulky stools or difficulty with bowel movements, and infertility. However, cystic fibrosis needs daily care, patients with the condition often have a better quality of life than people with cystic fibrosis had in previous decades. Improvements in treatments against cystic fibrosis has led people to live an increased lifespan.

The cystic fibrosis therapeutics market is expected to witness a substantial growth owing to the surge in incidence of cystic fibrosis. For instance, the disease affects around 30,000 people in the U.S. with around 1,000 new cases diagnosed each year. Of these new diagnoses, 75% are in children under the age of 2 years. Thereby, the U.S. government has made screening of cystic fibrosis compulsory for new born. There have been remarkable advancements in the field of cystic fibrosis treatment and the key market players are focusing toward the development of personalized drug therapy that is anticipated to propel the market growth in near future.

 

PURCHASE OPTIONS

Start reading instantly ,This title and over 12000 thousand more,available with Avenue Library, Subscription @ $699 T&C*

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,   
Int'l : +1-503-894-6022
( Europe )
+ 44-845-528-1300
Drop us an email at
help@alliedmarketresearch.com

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

FREQUENTLY ASKED
QUESTIONS?

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Sample

OR

Purchase Full Report of
Cystic Fibrosis (CF) Therapeutics Market

  • Online Only
  • $3,456
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $5,370
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,450
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $8,995
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library Membership
  • $0.00
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Start reading instantly.
    This title and over 12,000+ are available on the Avenue Library. Subscription @ $699 T&C*.

    Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts